drugset / Trial / NCT01962337

Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects

NCT01962337

Phase 1 Terminated 66 enrolled Five Prime Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3).

Timeline

Start
2013-10
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabiralizumab Monoclonal antibody Other

Indications